Medication Guide App

Remeron SolTab Side Effects

Generic Name: mirtazapine

Note: This page contains side effects data for the generic drug mirtazapine. It is possible that some of the dosage forms included below may not apply to the brand name Remeron SolTab.

It is possible that some side effects of Remeron SolTab may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to mirtazapine: oral tablet, oral tablet disintegrating

As well as its needed effects, mirtazapine (the active ingredient contained in Remeron SolTab) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking mirtazapine, check with your doctor immediately:

Less common
  • Decreased or increased movement
  • mood or mental changes, including abnormal thinking, agitation, anxiety, confusion, and feelings of not caring
  • shortness of breath
  • skin rash
  • swelling
Rare
  • Change in menstrual cycle (periods)
  • convulsions (seizures)
  • decreased sexual ability
  • menstrual pain
  • mood or mental changes, including anger, feelings of being outside the body, hallucinations (seeing, hearing, or feeling things that are not there), mood swings, and unusual excitement
  • mouth sores
  • sore throat, chills, or fever

Some mirtazapine side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common
  • Constipation
  • dizziness
  • drowsiness
  • dry mouth
  • increased appetite
  • weight gain
Less common
  • Abdominal or stomach pain
  • abnormal dreams
  • back pain
  • dizziness or fainting when getting up suddenly from a lying or sitting position
  • increased need to urinate
  • increased sensitivity to touch
  • increased thirst
  • low blood pressure
  • muscle pain
  • nausea
  • sense of constant movement of self or surroundings
  • trembling or shaking
  • vomiting
  • weakness

For Healthcare Professionals

Applies to mirtazapine: oral tablet, oral tablet disintegrating

Nervous system

Although the exact incidence has not been reported, paresthesia appears to be a relatively common side effect of mirtazapine (the active ingredient contained in Remeron SolTab) Patients typically experience paresthesia in the extremities or generalized in the body. However, several cases of oral paresthesia associated with the orally disintegrating tablet have been reported. Patients have described a sensation of swelling in the mouth, numbness, and anesthesia. The symptoms occur shortly after ingestion and resolve after a few hours.

Nearly all selective serotonin reuptake inhibitors, mixed serotonin/norepinephrine reuptake inhibitors, and tricyclic antidepressants cause sleep abnormalities to some extent. These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency (ROL)), both in healthy subjects and depressed patients. The antidepressants that increase serotonin function appear to have the greatest effect on REM sleep. The reduction in REM sleep is greatest early in treatment, but gradually returns towards baseline during long-term therapy; however, ROL remains long. Following discontinuation of therapy the amount of REM sleep tends to rebound. Some of these drugs (i.e., bupropion, mirtazapine, nefazodone, trazodone, trimipramine) appear to have a modest or minimal effect on REM sleep.

Nervous system side effects including somnolence (56%), headache (12%), dizziness (7% to 12%), insomnia (8%), abnormal dreams (4%), abnormal thinking (3%), confusion (2%), tremor (2%), sleep abnormalities, and paresthesia have been reported. Activation of mania and seizures have occurred rarely. One case of seizures, one case of akathisia, and one patient with a transient ischemic attack have also been reported.

Gastrointestinal

Gastrointestinal side effects including dry mouth (25%), increased appetite (17%), and constipation (13%) have been reported. Other reported gastrointestinal adverse effects have included diarrhea (9%), nausea (4%), vomiting, anorexia, cholecystitis, glossitis, and colitis. One case of subclinical pancreatitis has also been reported.

Metabolic

Metabolic side effects have been reported. Nonfasting triglyceride increases to greater than 20% above the normal upper limits have been reported in 15% of patients receiving mirtazapine (the active ingredient contained in Remeron SolTab) in clinical trials. Weight gain has been reported in 12% of patients. Less frequently reported were peripheral edema (2%), thirst, and weight loss. In one small study, mirtazapine appeared to improve glucose tolerance by reducing cortisol secretion.

Musculoskeletal

Numerous cases of mirtazapine- induced arthralgia have been reported. Symptoms tend to appear within 2 to 22 days of starting mirtazapine (the active ingredient contained in Remeron SolTab) and resolve shortly after discontinuation of treatment.

Musculoskeletal side effects including myalgia, arthralgia (2.4%), and myasthenia have been reported in less than 2% of patients receiving mirtazapine.

Hepatic

Hepatic side effects including liver function test abnormalities (primarily ALT (SGPT) elevations greater than three times normal concentrations) have been reported in 2% of patients receiving mirtazapine (the active ingredient contained in Remeron SolTab) Patients typically did not develop signs or symptoms of hepatic dysfunction

A case of mirtazapine- associated, dose-dependent asymptomatic elevation of liver enzymes has been reported. In this patient, elevated liver enzymes were discovered 3 months after starting mirtazapine (30 mg/day) and following a dose reduction (15 mg/day) liver enzymes decreased, but remained above normal. Liver enzymes returned to normal 2 months after discontinuation of mirtazapine.

Respiratory

Respiratory side effects including dyspnea (1%) have been reported.

Cardiovascular

Tachycardia, palpitation, chest pain, and postural hypotension were reported by at least 1% of patients in clinical trials, however, the incidence was less than that of placebo. ECG changes were also noted in 3% of patients. The incidence was similar to that of placebo and the changes were not considered clinically significant.

Cardiovascular side effects including hypertension, vasodilation, angina pectoris, bradycardia, and ventricular extrasystoles have been reported infrequently.

Hematologic

Hematologic and lymphatic side effects such as lymphadenopathy, leukopenia, anemia, petechiae, thrombocytopenia, lymphocytosis, and pancytopenia have been reported but are uncommon. Agranulocytosis occurred in two patients and neutropenia in one patient during premarketing clinical trials. One case of coagulopathy has been reported.

Coagulopathy (i.e., ecchymosis) developed in a patient three days after initiating mirtazapine therapy (30 mg/day). Following discontinuation of mirtazapine, prothrombin time, activated partial thromboplastin time, and international normalized ratio returned to normal and symptoms of ecchymosis disappeared.

Dermatologic

Dermatologic side effects including pruritus, rash, acne, dry skin, and alopecia have been reported infrequently. Postmarketing cases of severe skin reactions, including Stevens-Johnson Syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have also been reported.

General

General side effects have included asthenia (8%), flu syndrome (5%), and back pain (2%).

Ocular

Ocular side effects including eye pain, abnormality of accommodation, conjunctivitis, lacrimation, and glaucoma have been reported infrequently. A case of palinopsia has also been recorded.

Genitourinary

Genitourinary side effects including urinary frequency (2%), urinary tract infection, kidney calculus, cystitis, urinary incontinence, vaginitis, hematuria, impotence, and polyuria have been reported.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web4)